WALTHAM, Mass. / Oct 28, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
UBS Global Healthcare Conference 2025
Monday, November 10, 2025
8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
Jefferies 2025 London Healthcare Conference
Tuesday, November 18, 2025
2:00 p.m. GMT – Max Krakowiak
Citi's 2025 Global Healthcare Conference
Tuesday, December 2, 2025
9:00 a.m. ET – Prahlad Singh, president and chief executive officer
Attendees will receive an update on the Company and its strategic priorities during fireside chats.
Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$96.45 |
| Daily Change: | -0.71 -0.73 |
| Daily Volume: | 1,231,840 |
| Market Cap: | US$11.190B |
October 27, 2025 September 29, 2025 September 22, 2025 August 18, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load